FDA Approves First Combination Therapy For Initial Use In Patients With Moderate To Severe Hypertension

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for the antihypertensive agent AVALIDE for initial use in patients with hypertension who are likely to need multiple drugs to achieve their blood pressure goals.

The approval is based on data from two clinical trials involving more than 1,200 patients with moderate or severe high blood pressure.

FDA Approves First Combination Therapy For Initial Use In Patients With Moderate To Severe Hypertension